A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours

被引：0
|
作者：
Christophe Le Tourneau
Jean-Pierre Delord
Nuria Kotecki
Edith Borcoman
Carlos Gomez-Roca
Ségolène Hescot
Christiane Jungels
Anne Vincent-Salomon
Vincent Cockenpot
Lauriane Eberst
Audrey Molé
Wael Jdey
Françoise Bono
Véronique Trochon-Joseph
Hélène Toussaint
Christelle Zandanel
Olga Adamiec
Olivier de Beaumont
Philippe Alexandre Cassier
机构：
[1] Institut Curie,Department of Drug Development and Innovation (D3i)
[2] IUCT-Oncopole,Institut Claudius Régaud
[3] Institut Jules Bordet,Medical Oncology Clinic
[4] Institut Curie,Department of Tumor Biology
[5] Centre Léon Bérard,Medical Oncology
[6] Onxeo,Clinical Department
[7] Onxeo,Scientific Department
来源：
British Journal of Cancer | 2020年 / 123卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1481 / 1489
页数：8
相关论文
共 50 条
  • [41] First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
    Sullivan, Ryan J.
    Infante, Jeffrey R.
    Janku, Filip
    Wong, Deborah Jean Lee
    Sosman, Jeffrey A.
    Keedy, Vicki
    Patel, Manish R.
    Shapiro, Geoffrey I.
    Mier, James W.
    Tolcher, Anthony W.
    Wang-Gillam, Andrea
    Sznol, Mario
    Flaherty, Keith
    Buchbinder, Elizabeth
    Carvajal, Richard D.
    Varghese, Anna M.
    Lacouture, Mario E.
    Ribas, Antoni
    Patel, Sapna P.
    DeCrescenzo, Gary A.
    Emery, Caroline M.
    Groover, Anna L.
    Saha, Saurabh
    Varterasian, Mary
    Welsch, Dean J.
    Hyman, David M.
    Li, Bob T.
    CANCER DISCOVERY, 2018, 8 (02) : 184 - 195
  • [42] Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers
    Miyoshi, So
    Krishnaswami, Sriram
    Toyoizumi, Shigeyuki
    Nakamura, Hiroyuki
    Zwillich, Samuel H.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (01): : 11 - 20
  • [43] AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.
    Yap, Timothy A.
    Lakhani, Nehal J.
    Araujo, Daniel Vilarim
    Ahnert, Jordi Rodon
    Chandana, Sreenivasa R.
    Sharma, Manish
    Denis, Jean-Francois
    Gruosso, Tina
    Tremblay, Gilles
    O'Connor, Maureen
    Ghosh, Ria
    Sinclair, Sandra
    Wood, Debra L.
    Nadler, Paul, I
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours
    Li, H.
    Xu, J.
    Shao, B.
    Liu, R.
    Ran, R.
    Song, G.
    Jiang, H.
    Wang, K.
    Shi, Y.
    Liu, J.
    Hu, W.
    Chen, F.
    Zhang, G.
    Wang, Y.
    Zhao, C.
    Ru, J.
    Wang, Q.
    Rugo, H. S.
    Li, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single-agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595)
    Campone, Mario
    Plummer, Ruth
    Stephens, Peter
    Brakchi, Zahir
    Aissat-Daudigny, Louiza
    Kasiborski, Fabrice
    Cambois, Anne
    Moachon, Gilbert
    Brown, Peter D.
    Kayitalire, Louis
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.
    Janku, Filip
    Strauss, James
    Karim, Raghad
    Olszanski, Anthony J.
    Luke, Jason J.
    Leach, Kevin
    Iyer, Radhakrishnan
    Abbas, Atif
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    A. Craig Lockhart
    Shankar Sundaram
    John Sarantopoulos
    Monica M. Mita
    Andrea Wang-Gillam
    Jennifer L. Moseley
    Stephanie L. Barber
    Alex R. Lane
    Claudine Wack
    Laurent Kassalow
    Jean-François Dedieu
    Alain C. Mita
    Investigational New Drugs, 2014, 32 : 1236 - 1245
  • [48] A phase I dose-escalation study of the safety and pharmacokinetics of a novel spectrum selective kinase inhibitor, XL820, administered orally to patients with solid tumors
    Papadopoulos, K.
    Rodon, J.
    Mita, A.
    O'Rourke, P.
    Patnaik, A.
    Rubin, E.
    Tolcher, A.
    Stein, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 33 - 33
  • [49] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart, A. Craig
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Wang-Gillam, Andrea
    Moseley, Jennifer L.
    Barber, Stephanie L.
    Lane, Alex R.
    Wack, Claudine
    Kassalow, Laurent
    Dedieu, Jean-Francois
    Mita, Alain C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
  • [50] A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies.
    Salgia, Ravi
    Hong, David
    Sherman, Steven I.
    Ng, Chann
    Frye, John
    Janish, Linda
    Ratain, Mark
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3385S - 3385S
12345